These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32284682)

  • 1. Investigator Responsibilities in Clinical Research.
    Feehan AK; Garcia-Diaz J
    Ochsner J; 2020; 20(1):44-49. PubMed ID: 32284682
    [No Abstract]   [Full Text] [Related]  

  • 2. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research Misconduct in FDA-Regulated Clinical Trials: A Cross-sectional Analysis of Warning Letters and Disqualification Proceedings.
    Garmendia CA; Bhansali N; Madhivanan P
    Ther Innov Regul Sci; 2018 Sep; 52(5):592-605. PubMed ID: 29714564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective Analysis of Clinical Research Misconduct Using FDA-Issued Warning Letters and Clinical Investigator Inspection List From 2010 to 2014.
    Romano CA; Nair S; Delphin ES
    Anesth Analg; 2018 Mar; 126(3):976-982. PubMed ID: 29239950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responsibilities of university investigators when conducting trials on investigational new animal drugs.
    Parrott JC
    J Anim Sci; 1987 Aug; 65(2):577-80. PubMed ID: 3624100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigator responsibilities for clinical research studies: proper staffing can ensure an investigator is compliant.
    Kee AN
    J Med Pract Manage; 2011; 26(4):245-7. PubMed ID: 21506468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Food and Drug Administration guidance: supervisory responsibilities of investigators.
    Anderson C; Young PA; Berenbaum A
    J Diabetes Sci Technol; 2011 Mar; 5(2):433-8. PubMed ID: 21527116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Research Deviations in FDA-Regulated Clinical Trials: A Cross-Sectional Analysis of FDA Inspection Citations.
    Garmendia CA; Epnere K; Bhansali N
    Ther Innov Regul Sci; 2018 Sep; 52(5):579-591. PubMed ID: 29714561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trials in molecular imaging: the importance of following the protocol.
    Trembath L; Opanowski A;
    J Nucl Med Technol; 2011 Jun; 39(2):63-9. PubMed ID: 21565960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of data audits in detecting scientific misconduct. Results of the FDA program.
    Shapiro MF; Charrow RP
    JAMA; 1989 May; 261(17):2505-11. PubMed ID: 2704109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials integrity: a CRO perspective.
    Beach JE
    Account Res; 2001; 8(3):245-60. PubMed ID: 12481762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. U.S. Food and Drug Administration inspections of clinical investigators: overview of results from 1977 to 2009.
    Morgan-Linnell SK; Stewart DJ; Kurzrock R
    Clin Cancer Res; 2014 Jul; 20(13):3364-70. PubMed ID: 24737548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of clinical trials: A moving target.
    Bhatt A
    Perspect Clin Res; 2011 Oct; 2(4):124-8. PubMed ID: 22145122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research misconduct identified by the US Food and Drug Administration: out of sight, out of mind, out of the peer-reviewed literature.
    Seife C
    JAMA Intern Med; 2015 Apr; 175(4):567-77. PubMed ID: 25664866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data integrity-conduct of clinical investigations: university investigator perspective.
    Crooker BA; Preston RL; Boyd RD
    J Anim Sci; 1995 Feb; 73(2):622-7; discussion 627-8. PubMed ID: 7601799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of warning letters issued to clinical investigators by the United States Food and Drug Administration.
    Bramstedt KA
    Clin Invest Med; 2004 Jun; 27(3):129-34. PubMed ID: 15305804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continued investigator engagement: Reasons principal investigators conduct multiple FDA-regulated drug trials.
    Dombeck CB; Hinkley T; Fordyce CB; Blanchard K; Roe MT; Corneli A
    Contemp Clin Trials Commun; 2020 Mar; 17():100502. PubMed ID: 31890985
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.